Online inquiry

IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6808MR)

This product GTTS-WQ6808MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets STEAP1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_012449.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26872
UniProt ID Q9UHE8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6808MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2676MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ10884MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ927MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ13721MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ3353MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ12919MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ12005MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ10278MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFG 316
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW